Civitas wins $1M MJ Fox grant for Parkinson's drug; ALK-Abellos makes PhIII progress for drug against dust mite allergy;

@FierceBiotech: ICYMI this week's Industry Voices column - Ichorcumab: the blood of the gods? Feature | Follow @FierceBiotech

 @JohnCFierce: Sanofi - in need of some inspiration - partners with Curie Inst. on ovarian cancer targets. Release | Follow @JohnCFierce

@RyanMFierce: After Sanofi winds down manufacturing in Dagenham, U.K., what are the chances of a vibrant startup scene emerging there? More | Follow @RyanMFierce

 @EmilyMFierce: Biopharma tweeps, connect with colleagues and the editors of @FierceBiotech by joining our new LinkedIn group. | Follow @EmilyMFierce

> ALK-Abellos aims to pursue a European regulatory approval next year for its immunotherapy against dust mite allergies after a successful Phase III study. Item

> Paladin Labs (TSX:PLB) has garnered priority review from the FDA for its application for approval of Impavido for a parasitic disease known as leishmaniasis. Its PDUFA date is December 19, 2013. Item

> Civitas, an Alkermes ($ALKS) spinoff, has won a $1 million grant from Michael J. Fox's foundation to support clinical development of the startup's inhaled levodopa therapy for Parkinson's disease. Article

Pharma News

@FiercePharma: What we talk about when we talk about pharma. Commentary | Join our LinkedIn group | Follow @FiercePharma

@EricPFierce: Who manufacturers the top selling diabetes treatments? Novo has 5 of top 10 but not the top two. Special report | Follow @EricPFierce

> Lundbeck embarks on another restructuring, with more layoffs possible. Article

> State AGs ask Arkansas high court to back J&J's $1.2B Risperdal fine. More

> Needy Forest Labs reportedly eyeing bid for Elan. Story

Medical Device News

@FierceMedDev: Wright selling off hip and knee biz for $290M. Report | Follow @FierceMedDev

@DamianFierce: Japan's Terumo is adding 400+ jobs in an Irish R&D expansion. Yesterday's story | Follow @DamianFierce

@MichaelGFierce: Biosensor nanoparticles deliver cancer drug with precise, 3-D imaging. More | Follow @MichaelGFierce

> Brainsway partners up to push anti-depression tech in U.S. Article

> Mayo joins Sanovas to develop lung-clearing asthma treatment. Story

> Atossa teams with Thermo to market 'Pap smear for breast cancer.' News

Vaccines News

> CDC finds vaccines halved HPV infections in teenage girls. Report

> GSK's rotavirus vaccine as effective as Merck shot. Item

> Tax loophole eyed ahead of launch of Sanofi, GSK, AstraZeneca quadrivalent shots. More

> HPV vaccine pioneer targeting skin cancer jab. Story

> Japan withdraws recommendation of Merck and GSK HPV jabs. Article

> CDC readies for 4-in-1 flu vaccines. More

Pharma Manufacturing News

> GSK, Pfizer help start effort researching manufacturing innovations. Story

> Brazil to build Protalix a plant as part of sophisticated tech transfer. News

> Sanofi plant in London set to close by end of month. Article

> Gilead recalls 20 batches of AmBisome due to possible contamination. Report

And Finally… Canadian researchers have found that the brain can devise actions toward targets without the eye seeing them. Research

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.